Dr. Wolfgang Schnitzel, general manager of Shire Austria, and Karl-Heinz Hofbauer, site lead Vienna and managing director for the Technical Operations business, discuss the huge impact of Shire’s 32 billion USD acquisition of Baxalta that has grown the workforce from a few Shire employees in Austria to 3,500. Furthermore, they highlight the leading position Shire has in shaping the Austrian rare disease community and the company’s important role front in displaying Austria’s world-class production capabilities.
The big news for Shire globally is the 32 billion USD acquisition of Baxalta in 2016. How has this impacted the operations of Shire Austria?
"Shire started as a very small company in Austria; therefore, the global move to merge with Baxalta (formerly part of Baxter), which had a huge footprint here, was a game changer for us and is extremely exciting."
